Fluidigm to Participate at the 2020 Cantor Virtual Global Healthcare Conference
Fluidigm Corporation (Nasdaq: FLDM) announced participation in the Cantor Virtual Global Healthcare Conference, where management will provide updates on business strategy and financial performance. The formal presentation, led by President and CEO Chris Linthwaite, is scheduled for September 16, 2020, at 4:00 pm ET. A live webcast will be accessible, with a replay available for 90 days. Fluidigm focuses on translational and clinical research, utilizing proprietary technologies to enhance health insights and accelerate therapy development.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in investor meetings and present updates regarding Fluidigm’s business strategy and financial performance at the Cantor Virtual Global Healthcare Conference.
Chris Linthwaite, President and Chief Executive Officer, will give a formal presentation on Wednesday, September 16, 2020, at 4:00 pm ET. A live webcast of the company’s presentation and subsequent replay will be available in the Events & Presentations section of the Company’s investor website. The webcast will be archived for 90 days following the live presentation.
About Fluidigm
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Available Information
We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Contact:
Fluidigm Corporation
Agnes Lee
Vice President, Investor Relations
650 416 7423
agnes.lee@fluidigm.com
FAQ
When will Fluidigm present at the Cantor Virtual Global Healthcare Conference?
Where can I watch Fluidigm's presentation after it happens?
What is Fluidigm's focus in biotechnology?
Who is presenting for Fluidigm at the conference?
What technologies does Fluidigm use for its solutions?
